Melissa Busch[email protected]Top StoriesFDA ClearancePillar Biosciences gets FDA approval for NGS solid tumor profiling testPillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.ValidationImmunovia announces positive results for next-gen pancreatic cancer testCollaborationVertex to pay $25M upfront to scale cell manufacturing technologyMergers & AcquisitionsLabcorp buys Invitae portfolio for $239MSponsor ContentVisit our Molecular Diagnostics Community